Pliant Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pliant Therapeutics, Inc.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Plus deals involving Aculys/Neurelis, Xtalpi/Excelra, Abbisko/Lilly, Daiichi Sankyo/Cosette, Mitsubishi Tanabe/ADC Therapeutics and PersonGen/Transgene.
With the Lunar New Year just around the corner, Chinese biotechs have raised a total of $740m through initial public offerings and 10 other fundraising deals.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.